In summary, our data in primary neoplastic B-cells is consistent with findings by others that pevonedistat enhances the anti-tumor activity of TRAIL in solid tumor cell lines [56], thus suggesting that pevonedistat should be further investigated in therapy of CLL and NHL. Here, TNFSF10 is linked to non-Hodgkin lymphoma.